BioCentury
ARTICLE | Company News

BARDA, Genentech partner against influenza, health security threats

October 5, 2018 7:31 PM UTC

HHS’s Biomedical Advanced Research and Development Authority and Genentech Inc. partnered to develop products to fight influenza and other health security threats.

BARDA initially will provide $43 million over five years to develop baloxavir marboxil to treat severely ill patients hospitalized with seasonal or pandemic influenza infections and $19 million over 19 months to support the development of alteplase to treat lung injuries caused by sulfur mustard gas...

BCIQ Company Profiles

Genentech Inc.